Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Fondazione EMN Italy Onlus
- Target Recruit Count
- 9
- Registration Number
- NCT03440411
- Locations
- 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2018-02-20
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03439280
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
🇺🇸Weill Cornell Medical Center, Div. of Hematology Medical Oncology, New York, New York, United States
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 174
- Registration Number
- NCT03287908
- Locations
- 🇨🇦
University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸Winship Cancer Institute Emory U, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center - Multiple Myeloma Research Consortium, Chicago, Illinois, United States
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Celgene
- Target Recruit Count
- 53
- Registration Number
- NCT03257631
- Locations
- 🇫🇷
Local Institution - 101, Villejuif CEDEX, France
🇪🇸Local Institution - 302, Barcelona, Spain
🇫🇷Local Institution - 105, Vandoeuvre les Nancy, France
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT03227432
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 8
- Registration Number
- NCT03202628
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone
- Conditions
- Interventions
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 304
- Registration Number
- NCT03180736
- Locations
- 🇮🇹
Ancona, Ancona, Italy
🇮🇹Brescia, Brescia, Italy
🇨🇿Praha 2, Praha, Czechia
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-05-31
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT03170882
- Locations
- 🇮🇹
Centro Di Riferimento Oncologico, Aviano, Italy
🇮🇹Azienda Ospedaliero Universitaria Di Bologna - Policlinico S Orsola Malpighi, Bologna, Emilia-Romagna, Italy
🇨🇦Lakeridge Health Center, Ottawa, Ontario, Canada
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 495
- Registration Number
- NCT03151811
- Locations
- 🇨🇿
CZ-01, Ostrava, Czechia
🇺🇸US-19, Plantation, Florida, United States
🇺🇸US01, Fresno, California, United States
Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Koen van Besien
- Target Recruit Count
- 18
- Registration Number
- NCT03143985
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.